SCHEMBL5049657

SCHEMBL5049657

CN(C)CCSc1ccc(Nc2ncnc(OC3CCNCC3)c2C#N)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 17/20 0.42
EGFR P00533 3/20 0.37
FGFR1 P11362 3/20 0.37
FLT1 P17948 3/20 0.37
FLT4 P35916 3/20 0.37
KDR P35968 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390818 0.84 GPR119 (0.59) GPR119
SCHEMBL3167373 0.82 GPR119 (0.49) GPR119
SCHEMBL6065464 0.80 GPR119 (0.44) GPR119EGFRFGFR1FLT1FLT4
SCHEMBL5048834 0.78 GPR119 (0.54) GPR119
SCHEMBL5052397 0.76 GPR119 (0.51) GPR119EGFRFGFR1FLT1FLT4
SCHEMBL5048756 0.74 GPR119 (0.67) GPR119EGFRFGFR1FLT1FLT4
SCHEMBL391562 0.70 GPR119 (0.61) GPR119
SCHEMBL3164053 0.68 GPR119 (0.50) GPR119
SCHEMBL13022148 0.68 GPR119 (0.65) GPR119
SCHEMBL5190095 0.68 GPR119 (0.37) GPR119EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed